CERE News and Press, Ceres Inc. From 11/01/23

Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon investor webcast scheduled for December 11, 2023 Conference ...

Cerevel Therapeutics Holdings Inc. (CERE) is expected to report $-0.63 for Q3 2023

2023-10-18 07:07:15 ET More on Cerevel Therapeutics Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity Cerevel Therapeutics prices $450M stock For further details see: Cerevel Therapeutics says Perceptive Advisors buys 876.8K shares

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wedn...

2023-10-12 05:30:22 ET More on Cerevel Therapeutics Cerevel: Drop On Data Delay For EMPOWER Program Provides Buy Opportunity Cerevel downgraded at Bank of America on delayed readouts Cerevel Therapeutics falls on delayed data readouts Seeking Alpha’s Q...

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 19,728,189 s...

2023-10-11 16:05:17 ET More on Cerevel Therapeutics Cerevel downgraded at Bank of America on delayed readouts Seeking Alpha’s Quant Rating on Cerevel Therapeutics Cerevel Therapeutics falls on delayed data readouts For further details see: Cerevel ...

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 21st Annual Global Healt...

NEW YORK, NY / ACCESSWIRE / August 9, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE). Investors who purchased Cerevel securities are encouraged to obtain add...

2023-08-04 13:26:12 ET Summary Cerevel Therapeutics Holdings, Inc. experienced a drop in shares due to a delay in releasing top-line results from studies on emraclidine for schizophrenia treatment. Emraclidine is also being developed for Alzheimer's Disease Psychosis, with a phase...